Healthcare Business

The Top 5 Analyst Calls of the Week, Or Top 6 Calls (FFIV, MNKD, PDLI, SBIB, CMA, GOOG, AAPL)

We always look for standout research calls.  The goal is not to just find bullish calls, but calls which have a longer duration of a single trading session or even a single week.  The top standout calls this last week came in shares of F5 Networks, Inc. (NASDAQ: FFIV), MannKind Corporation (NASDAQ: MNKD), PDL BioPharma, Inc. (NASDAQ: PDLI), Sterling Bancshares, Inc. (NASDAQ: SBIB), Google Inc. (NASDAQ: GOOG), and Apple Inc. (NASDAQ: AAPL).

F5 Networks, Inc. (NASDAQ: FFIV) had a very rough week and shares were  battered after its revenue shortfall and mixed guidance was just nowhere near good  enough to satisfy investors after what had been close to a 200% return in the last year.  Many firms threw in the towel as shares went from almost $140 to under $110 and the stock closed out the week at $109.97 versus a 52-week range of $47.11 to $145.76.  We saw two standout calls actually getting behind the network optimization solutions provider.  F5 was raised to “Outperform” from “Neutral and the price target was raised to $134.00 from $103.00 by Credit Suisse.  The firm called it a buying opportunity and a chance to accumulate shares.  Gleacher & Co. also stepped in and upgraded the rating on F5 to “Buy” from “Hold” with a $130.00 price target due to its market position and due to still well above-market growth even if that growth is decelerating.

MannKind Corporation (NASDAQ: MNKD) was one that felt like no Kind man this week.  The company’s inhalable diabetes treatment called Afrezza was given yet another blow by the FDA. In a complete response letter, the FDA asked for two more tests, which will likely cost more capital than MannKind has available today.  Shares were as high as $9.50 before the pre-halt and before the news hit and shares actually hit $10.00 on Tuesday.  After the halt was released, MannKind opened down close to $5.00 on Thursday and shares closed the week out at $5.76 after having briefly challenged $6.00 on Thursday and Friday.  We knew downgrades would come, and we gave our own detailed outlook over at  Still, there was a standout gutsy call made elsewhere this week from a brokerage and research firm we rarely here about.  A firm called Weeden & Co. upgraded the shares from Hold to Buy and raised the price target from $6.00 to $9.00.  Apparently the only thing at issue was that the firm did not have a sell rating before, although most traders and investors treat a “hold” rating the same as a “sell” rating.  Dangerous times for a dangerous stock, but one gutsy call.

Sponsored: Tips for Investing

A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.

Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.